Effect of Antiretroviral Therapy on Bone Turnover and Bone Mineral Density in Men with Primary HIV-1 Infection

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Mar 10

PMID 29522570

Citations 10

Authors

Mariska C Vlot

Marlous L Grijsen

Jan M Prins

Renate T de Jongh

Robert de Jonge

Martin den Heijer

Annemieke C Heijboer

Affiliations

Soon will be listed here.

Abstract

Introduction: Previous studies indicate that human immunodeficiency virus (HIV)-infection and combination antiretroviral therapy (cART) can affect bone turnover. Furthermore, HIV-infected patients have lower bone mineral density (BMD) compared to a healthy reference population.

Objective: To evaluate the longitudinal effect of HIV-infection and cART on bone turnover markers (BTMs) and BMD in men with primary HIV-infection (PHI).

Design, Methods: Thirty-five PHI-men were divided into two groups, those that received cART for the first time (n = 26) versus no-cART (n = 9). Dual-energy X-ray absorptiometry (DXA) was performed on femoral neck (FN), total hip (TH) and lumbar spine (LS) and BTMs (P1NP, alkaline phosphatase, osteocalcin, ICTP and CTX) were measured at baseline and follow-up.

Results: At baseline, the median CD4+ T-cell count was 455 cells/mm3 (IQR 320-620) and plasma viral load 5.4 log10 copies/mL (IQR 4.7-6.0) in the cART treated group, compared to 630 (IQR 590-910) and 4.8 (IQR 4.2-5.1) in the untreated group. The median follow-up time was 60.7 weeks (IQR 24.7-96.0). All BTMs, except ICTP, showed a significant increase during cART versus no changes of BTMs in the untreated group. FN and TH BMD showed a significant decrease in both groups. LS BMD did not change in both groups.

Conclusion: Bone turnover increased in PHI-men treated with cART which was accompanied by a decrease in FN and TH BMD. No increase of bone turnover was seen in untreated PHI-men. Our study suggests that cART results in increased bone turnover and decreased BMD of the hip in PHI-men.

Citing Articles

Bone Disease in HIV: Need for Early Diagnosis and Prevention.

Schinas G, Schinas I, Ntampanlis G, Polyzou E, Gogos C, Akinosoglou K Life (Basel). 2024; 14(4).

PMID: 38672792 PMC: 11051575. DOI: 10.3390/life14040522.

Evaluation of bone mineral density, microarchitecture, and detection of fractures on young patients living with human immunodeficiency virus: when and how to screen?.

Gehrke B, Farias M, Wildemberg L, Ferraiuoli G, Ribeiro V, Bosgnoli R Endocrine. 2023; 83(1):214-226.

PMID: 37673836 DOI: 10.1007/s12020-023-03501-9.

Bone Mineral Content Estimation in People Living with HIV: Prediction and Validation of Sex-Specific Anthropometric Models.

Correia I, Navarro A, Cordeiro J, Gomide E, Mazzonetto L, Oliveira A Int J Environ Res Public Health. 2022; 19(19).

PMID: 36231634 PMC: 9566219. DOI: 10.3390/ijerph191912336.

Secondary Osteoporosis and Metabolic Bone Diseases.

Sobh M, Abdalbary M, Elnagar S, Nagy E, Elshabrawy N, Abdelsalam M J Clin Med. 2022; 11(9).

PMID: 35566509 PMC: 9102221. DOI: 10.3390/jcm11092382.

Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA.

Tasca K, Fagundes Vidal V, Manfio V, Barbosa A, de Souza L J Appl Biomed. 2021; 19(1):73-82.

PMID: 34907718 DOI: 10.32725/jab.2021.002.

References

Grant P, Cotter A . Tenofovir and bone health. Curr Opin HIV AIDS. 2016; 11(3):326-32. PMC: 4844450. DOI: 10.1097/COH.0000000000000248. View

Piso R, Rothen M, Rothen J, Stahl M . Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr. 2011; 56(4):320-4. DOI: 10.1097/QAI.0b013e31820cf010. View

Brown T, Ross A, Storer N, Labbato D, McComsey G . Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther. 2011; 16(7):1063-72. PMC: 3915418. DOI: 10.3851/IMP1874. View

Grant P, Kitch D, McComsey G, Collier A, Koletar S, Erlandson K . Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. J Infect Dis. 2016; 214(4):607-11. PMC: 4957444. DOI: 10.1093/infdis/jiw204. View

Grijsen M, Steingrover R, Wit F, Jurriaans S, Verbon A, Brinkman K . No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012; 9(3):e1001196. PMC: 3313945. DOI: 10.1371/journal.pmed.1001196. View

Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F . Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS. 2016; 30(3):405-14. PMC: 4712729. DOI: 10.1097/QAD.0000000000000918. View

De Clercq E . Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016; 119:1-7. DOI: 10.1016/j.bcp.2016.04.015. View

Ray A, Fordyce M, Hitchcock M . Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2015; 125:63-70. DOI: 10.1016/j.antiviral.2015.11.009. View

Bolland M, Grey A, Reid I . Skeletal health in adults with HIV infection. Lancet Diabetes Endocrinol. 2014; 3(1):63-74. DOI: 10.1016/S2213-8587(13)70181-5. View

10.

Madeddu G, Spanu A, Solinas P, Calia G, Lovigu C, Chessa F . Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004; 48(1):39-48. View

11.

Cotter E, Malizia A, Chew N, Powderly W, Doran P . HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses. 2007; 23(12):1521-30. DOI: 10.1089/aid.2007.0112. View

12.

Grijsen M, Vrouenraets S, Wit F, Stolte I, Prins M, Lips P . Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis. 2012; 207(3):386-91. DOI: 10.1093/infdis/jis687. View

13.

Amiel C, Ostertag A, Slama L, Baudoin C, Nguyen T, Lajeunie E . BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004; 19(3):402-9. DOI: 10.1359/JBMR.0301246. View

14.

Almansouri A, Abdulfatah M, Baaqil O, Bakheet A, Turki S, Kotb M . Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry. J Bone Metab. 2016; 23(1):16-22. PMC: 4791433. DOI: 10.11005/jbm.2016.23.1.16. View

15.

Spanu A, Solinas P, Babudieri S, Calia G, Lovigu C, Mannazzu M . Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2015; 19(23):4576-89. View

16.

Grijsen M, Vrouenraets S, Steingrover R, Lips P, Reiss P, Wit F . High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS. 2010; 24(14):2233-8. DOI: 10.1097/QAD.0b013e32833c93fe. View

17.

Bolland M, Grey A, Horne A, Briggs S, Thomas M, Ellis-Pegler R . Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf). 2007; 67(2):270-5. DOI: 10.1111/j.1365-2265.2007.02875.x. View

18.

Zhang L, Su Y, Hsieh E, Xia W, Xie J, Han Y . Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study. BMC Musculoskelet Disord. 2013; 14:224. PMC: 3734166. DOI: 10.1186/1471-2474-14-224. View

19.

Alvarez E, Belloso W, Boyd M, Inkaya A, Hsieh E, Kambugu A . Which HIV patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS. 2016; 11(3):268-76. DOI: 10.1097/COH.0000000000000269. View

20.

Marques de Menezes E, Machado A, Barbosa Jr F, de Paula F, Navarro A . Bone metabolism dysfunction mediated by the increase of proinflammatory cytokines in chronic HIV infection. J Bone Miner Metab. 2016; 35(2):234-242. DOI: 10.1007/s00774-016-0749-8. View